TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.

Blood Adv · 2022 · PMC9092405 · PMID 35073573

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0800

boldest claim

The sentences

showed a trendP = .05actually significant

Comparing OS of all patients based on TP53 mutation status showed that no TP53 mutation (median, 33.9 months) vs TP53 monoallelic (median, 12.5 months) vs TP53 multihit (median, 9.4 months) was significant ( P < .0001) ( Figure 2D ), whereas comparison of TP53 monoallelic vs multihit showed a trend toward worse outcome ( P = .05).

also in 53,322 other papers

borderline significanceP = .08so close (0.05 < p ≤ 0.1)

There was no difference in OS between AML and all MDS ( P = .36) or between MDS-SLD/MLD (13.2 months) vs MDS-EB (10.7 months) vs AML (8.3 months) ( P = .16) groups, although there was borderline significance when comparing OS of AML patients to MDS-SLD/MLD patients ( P = .08).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.